Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment

Jian Ting Zhang, Yang Liu

Research output: Contribution to journalReview article

44 Scopus citations


Drug resistance is a major problem in successful cancer chemotherapy. Many molecular mechanisms that are responsible for drug resistance are known whereas others have yet to be discovered. Determining the exact mechanism activated in a particular case (clinical or laboratory) is a difficult task. Recently, proteomics has been applied to investigate drug resistance mechanisms in model cancer cell lines. As a result, novel mechanisms of resistance have been discovered and known mechanisms of resistance confirmed. In this paper, we wish to review recent developments and progresses in the application of proteomic tools to identify known and novel drug resistance mechanisms in drug-selected model cancer cell lines. Our combined analyses of multiple proteomic studies of various drug resistant cancer cell lines revealed that many mechanisms of resistance likely exist in any given drug-selected cancer cell line and that common mechanisms of resistance may be selected in a spectrum of cancer cell lines. These observations suggest that combination therapies targeting multiple mechanisms to sensitize drug resistant cancers may be necessary to eradicate cancers in the future.

Original languageEnglish (US)
Pages (from-to)741-756
Number of pages16
JournalCancer Treatment Reviews
Issue number8
StatePublished - Dec 1 2007


  • 2-Dimensional gel electrophoresis
  • Cancer chemotherapy
  • Drug resistance
  • Mass spectrometry
  • Proteomics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment'. Together they form a unique fingerprint.

  • Cite this